Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double‐blind, randomized, controlled study
This study evaluated the potential effectiveness of different doses of Eriomin® on hyperglycemia and insulin resistance associated with other metabolic biomarkers in prediabetic individuals. Prediabetes patients (n = 103, 49 ± 10 years) were randomly divided into four parallel groups: (a) Placebo; (...
Gespeichert in:
| Veröffentlicht in: | Phytotherapy research 2019-07, Vol.33 (7), p.1921-1933 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1933 |
|---|---|
| container_issue | 7 |
| container_start_page | 1921 |
| container_title | Phytotherapy research |
| container_volume | 33 |
| creator | Ribeiro, Carolina B. Ramos, Fernanda M. Manthey, John A. Cesar, Thais B. |
| description | This study evaluated the potential effectiveness of different doses of Eriomin® on hyperglycemia and insulin resistance associated with other metabolic biomarkers in prediabetic individuals. Prediabetes patients (n = 103, 49 ± 10 years) were randomly divided into four parallel groups: (a) Placebo; (b) Eriomin 200 mg; (c) Eriomin 400 mg; and (d) Eriomin 800 mg. Assessment of biochemical, metabolic, inflammatory, hepatic, renal, anthropometric markers, blood pressure, and dietary parameters were performed during 12 weeks of intervention. Treatment with all doses of Eriomin (200, 400, and 800 mg) had similar effects and altered significantly the following variables: blood glucose (−5%), insulin resistance (−7%), glucose intolerance (−7%), glycated hemoglobin (−2%), glucagon (−6.5%), C‐peptide (−5%), hsCRP (−12%), interleukin‐6 (−13%), TNFα (−11%), lipid peroxidation (−17%), systolic blood pressure (−8%), GLP‐1 (+15%), adiponectin (+19%), and antioxidant capacity (+6%). Eriomin or placebo did not influence the anthropometric and dietary variables. Short‐term intervention with Eriomin, at doses of 200, 400, or 800 mg/day, benefited glycemic control, reduced systemic inflammation and oxidative stress, and reversed the prediabetic condition in 24% of the evaluated patients. |
| doi_str_mv | 10.1002/ptr.6386 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6618084</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2265596499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4386-bcd6a63e68decc7de7f5ab5ebd6eea6fe7c86ea93af6c3418a0276c10ec8077e3</originalsourceid><addsrcrecordid>eNp1kc1qFTEYhoMo9rQKXoEE3LhwajKZyUxcFEo5_kBBkQruQib55jQlk4zJzJFx1bUrr8SL8FK8EnNsrT_gKh_k-R6-lxehB5QcUkLKp-MUDzlr-S20okSIgtYNu41WRNS0qGj7fg_tp3RBCBElqe6iPUZpy0RJV-jzuu9BT3YLHlLCocfraMNg_bev2Ho8KK821m_w-TJC3LhFw2AVVt7gCFuISbndzhjBWNXBBAnr4I2dbPDP8DE2Ye4cfL_80jnrzRMc82a2f4I8Z3CKwTkwOE2zWe6hO71yCe5fvwfo3fP12cnL4vT1i1cnx6eFrnLEotOGK86Atwa0bgw0fa26GjrDARTvodEtByWY6rlmOb0iZcM1JaBb0jTADtDRlXecuwGMhnyGcnKMdlBxkUFZ-fePt-dyE7aSc9qStsqCx9eCGD7MkCY52KTBOeUhzEmWJees4rypM_roH_QizNHneDuqrgWvhPgt1DGkFKG_OYYSuStY5oLlruCMPvzz-BvwV6MZKK6Aj9bB8l-RfHP29qfwBwmOtiM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2265596499</pqid></control><display><type>article</type><title>Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double‐blind, randomized, controlled study</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Ribeiro, Carolina B. ; Ramos, Fernanda M. ; Manthey, John A. ; Cesar, Thais B.</creator><creatorcontrib>Ribeiro, Carolina B. ; Ramos, Fernanda M. ; Manthey, John A. ; Cesar, Thais B.</creatorcontrib><description>This study evaluated the potential effectiveness of different doses of Eriomin® on hyperglycemia and insulin resistance associated with other metabolic biomarkers in prediabetic individuals. Prediabetes patients (n = 103, 49 ± 10 years) were randomly divided into four parallel groups: (a) Placebo; (b) Eriomin 200 mg; (c) Eriomin 400 mg; and (d) Eriomin 800 mg. Assessment of biochemical, metabolic, inflammatory, hepatic, renal, anthropometric markers, blood pressure, and dietary parameters were performed during 12 weeks of intervention. Treatment with all doses of Eriomin (200, 400, and 800 mg) had similar effects and altered significantly the following variables: blood glucose (−5%), insulin resistance (−7%), glucose intolerance (−7%), glycated hemoglobin (−2%), glucagon (−6.5%), C‐peptide (−5%), hsCRP (−12%), interleukin‐6 (−13%), TNFα (−11%), lipid peroxidation (−17%), systolic blood pressure (−8%), GLP‐1 (+15%), adiponectin (+19%), and antioxidant capacity (+6%). Eriomin or placebo did not influence the anthropometric and dietary variables. Short‐term intervention with Eriomin, at doses of 200, 400, or 800 mg/day, benefited glycemic control, reduced systemic inflammation and oxidative stress, and reversed the prediabetic condition in 24% of the evaluated patients.</description><identifier>ISSN: 0951-418X</identifier><identifier>EISSN: 1099-1573</identifier><identifier>DOI: 10.1002/ptr.6386</identifier><identifier>PMID: 31183921</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adiponectin ; Adult ; Anthropometry ; Antioxidants ; Biomarkers ; Blood glucose ; Blood Glucose - metabolism ; Blood pressure ; Citrus ; Diet ; Double-Blind Method ; Double-blind studies ; Female ; Flavanones - therapeutic use ; flavonoids ; Glucagon ; Glucose ; Glucose tolerance ; Glycated Hemoglobin A - metabolism ; Hemoglobin ; Hesperidin - therapeutic use ; Humans ; Hyperglycemia ; Hyperglycemia - drug therapy ; Hypoglycemic Agents - therapeutic use ; Inflammation ; Insulin ; Insulin Resistance ; Interleukins ; Intervention ; Intolerance ; Lipid peroxidation ; Lipids ; Male ; Metabolism ; Middle Aged ; Oxidative stress ; Peroxidation ; prediabetic state ; Prediabetic State - drug therapy ; Treatment Outcome ; Tumor necrosis factor-α</subject><ispartof>Phytotherapy research, 2019-07, Vol.33 (7), p.1921-1933</ispartof><rights>2019 The Authors Phytotherapy Research Published by John Wiley & Sons Ltd</rights><rights>2019 The Authors Phytotherapy Research Published by John Wiley & Sons Ltd.</rights><rights>2019. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4386-bcd6a63e68decc7de7f5ab5ebd6eea6fe7c86ea93af6c3418a0276c10ec8077e3</citedby><cites>FETCH-LOGICAL-c4386-bcd6a63e68decc7de7f5ab5ebd6eea6fe7c86ea93af6c3418a0276c10ec8077e3</cites><orcidid>0000-0001-9122-0460 ; 0000-0001-7878-7075</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fptr.6386$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fptr.6386$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31183921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ribeiro, Carolina B.</creatorcontrib><creatorcontrib>Ramos, Fernanda M.</creatorcontrib><creatorcontrib>Manthey, John A.</creatorcontrib><creatorcontrib>Cesar, Thais B.</creatorcontrib><title>Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double‐blind, randomized, controlled study</title><title>Phytotherapy research</title><addtitle>Phytother Res</addtitle><description>This study evaluated the potential effectiveness of different doses of Eriomin® on hyperglycemia and insulin resistance associated with other metabolic biomarkers in prediabetic individuals. Prediabetes patients (n = 103, 49 ± 10 years) were randomly divided into four parallel groups: (a) Placebo; (b) Eriomin 200 mg; (c) Eriomin 400 mg; and (d) Eriomin 800 mg. Assessment of biochemical, metabolic, inflammatory, hepatic, renal, anthropometric markers, blood pressure, and dietary parameters were performed during 12 weeks of intervention. Treatment with all doses of Eriomin (200, 400, and 800 mg) had similar effects and altered significantly the following variables: blood glucose (−5%), insulin resistance (−7%), glucose intolerance (−7%), glycated hemoglobin (−2%), glucagon (−6.5%), C‐peptide (−5%), hsCRP (−12%), interleukin‐6 (−13%), TNFα (−11%), lipid peroxidation (−17%), systolic blood pressure (−8%), GLP‐1 (+15%), adiponectin (+19%), and antioxidant capacity (+6%). Eriomin or placebo did not influence the anthropometric and dietary variables. Short‐term intervention with Eriomin, at doses of 200, 400, or 800 mg/day, benefited glycemic control, reduced systemic inflammation and oxidative stress, and reversed the prediabetic condition in 24% of the evaluated patients.</description><subject>Adiponectin</subject><subject>Adult</subject><subject>Anthropometry</subject><subject>Antioxidants</subject><subject>Biomarkers</subject><subject>Blood glucose</subject><subject>Blood Glucose - metabolism</subject><subject>Blood pressure</subject><subject>Citrus</subject><subject>Diet</subject><subject>Double-Blind Method</subject><subject>Double-blind studies</subject><subject>Female</subject><subject>Flavanones - therapeutic use</subject><subject>flavonoids</subject><subject>Glucagon</subject><subject>Glucose</subject><subject>Glucose tolerance</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Hemoglobin</subject><subject>Hesperidin - therapeutic use</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hyperglycemia - drug therapy</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Inflammation</subject><subject>Insulin</subject><subject>Insulin Resistance</subject><subject>Interleukins</subject><subject>Intervention</subject><subject>Intolerance</subject><subject>Lipid peroxidation</subject><subject>Lipids</subject><subject>Male</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Oxidative stress</subject><subject>Peroxidation</subject><subject>prediabetic state</subject><subject>Prediabetic State - drug therapy</subject><subject>Treatment Outcome</subject><subject>Tumor necrosis factor-α</subject><issn>0951-418X</issn><issn>1099-1573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1qFTEYhoMo9rQKXoEE3LhwajKZyUxcFEo5_kBBkQruQib55jQlk4zJzJFx1bUrr8SL8FK8EnNsrT_gKh_k-R6-lxehB5QcUkLKp-MUDzlr-S20okSIgtYNu41WRNS0qGj7fg_tp3RBCBElqe6iPUZpy0RJV-jzuu9BT3YLHlLCocfraMNg_bev2Ho8KK821m_w-TJC3LhFw2AVVt7gCFuISbndzhjBWNXBBAnr4I2dbPDP8DE2Ye4cfL_80jnrzRMc82a2f4I8Z3CKwTkwOE2zWe6hO71yCe5fvwfo3fP12cnL4vT1i1cnx6eFrnLEotOGK86Atwa0bgw0fa26GjrDARTvodEtByWY6rlmOb0iZcM1JaBb0jTADtDRlXecuwGMhnyGcnKMdlBxkUFZ-fePt-dyE7aSc9qStsqCx9eCGD7MkCY52KTBOeUhzEmWJees4rypM_roH_QizNHneDuqrgWvhPgt1DGkFKG_OYYSuStY5oLlruCMPvzz-BvwV6MZKK6Aj9bB8l-RfHP29qfwBwmOtiM</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Ribeiro, Carolina B.</creator><creator>Ramos, Fernanda M.</creator><creator>Manthey, John A.</creator><creator>Cesar, Thais B.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9122-0460</orcidid><orcidid>https://orcid.org/0000-0001-7878-7075</orcidid></search><sort><creationdate>201907</creationdate><title>Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double‐blind, randomized, controlled study</title><author>Ribeiro, Carolina B. ; Ramos, Fernanda M. ; Manthey, John A. ; Cesar, Thais B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4386-bcd6a63e68decc7de7f5ab5ebd6eea6fe7c86ea93af6c3418a0276c10ec8077e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adiponectin</topic><topic>Adult</topic><topic>Anthropometry</topic><topic>Antioxidants</topic><topic>Biomarkers</topic><topic>Blood glucose</topic><topic>Blood Glucose - metabolism</topic><topic>Blood pressure</topic><topic>Citrus</topic><topic>Diet</topic><topic>Double-Blind Method</topic><topic>Double-blind studies</topic><topic>Female</topic><topic>Flavanones - therapeutic use</topic><topic>flavonoids</topic><topic>Glucagon</topic><topic>Glucose</topic><topic>Glucose tolerance</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Hemoglobin</topic><topic>Hesperidin - therapeutic use</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hyperglycemia - drug therapy</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Inflammation</topic><topic>Insulin</topic><topic>Insulin Resistance</topic><topic>Interleukins</topic><topic>Intervention</topic><topic>Intolerance</topic><topic>Lipid peroxidation</topic><topic>Lipids</topic><topic>Male</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Oxidative stress</topic><topic>Peroxidation</topic><topic>prediabetic state</topic><topic>Prediabetic State - drug therapy</topic><topic>Treatment Outcome</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ribeiro, Carolina B.</creatorcontrib><creatorcontrib>Ramos, Fernanda M.</creatorcontrib><creatorcontrib>Manthey, John A.</creatorcontrib><creatorcontrib>Cesar, Thais B.</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Phytotherapy research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ribeiro, Carolina B.</au><au>Ramos, Fernanda M.</au><au>Manthey, John A.</au><au>Cesar, Thais B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double‐blind, randomized, controlled study</atitle><jtitle>Phytotherapy research</jtitle><addtitle>Phytother Res</addtitle><date>2019-07</date><risdate>2019</risdate><volume>33</volume><issue>7</issue><spage>1921</spage><epage>1933</epage><pages>1921-1933</pages><issn>0951-418X</issn><eissn>1099-1573</eissn><abstract>This study evaluated the potential effectiveness of different doses of Eriomin® on hyperglycemia and insulin resistance associated with other metabolic biomarkers in prediabetic individuals. Prediabetes patients (n = 103, 49 ± 10 years) were randomly divided into four parallel groups: (a) Placebo; (b) Eriomin 200 mg; (c) Eriomin 400 mg; and (d) Eriomin 800 mg. Assessment of biochemical, metabolic, inflammatory, hepatic, renal, anthropometric markers, blood pressure, and dietary parameters were performed during 12 weeks of intervention. Treatment with all doses of Eriomin (200, 400, and 800 mg) had similar effects and altered significantly the following variables: blood glucose (−5%), insulin resistance (−7%), glucose intolerance (−7%), glycated hemoglobin (−2%), glucagon (−6.5%), C‐peptide (−5%), hsCRP (−12%), interleukin‐6 (−13%), TNFα (−11%), lipid peroxidation (−17%), systolic blood pressure (−8%), GLP‐1 (+15%), adiponectin (+19%), and antioxidant capacity (+6%). Eriomin or placebo did not influence the anthropometric and dietary variables. Short‐term intervention with Eriomin, at doses of 200, 400, or 800 mg/day, benefited glycemic control, reduced systemic inflammation and oxidative stress, and reversed the prediabetic condition in 24% of the evaluated patients.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31183921</pmid><doi>10.1002/ptr.6386</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-9122-0460</orcidid><orcidid>https://orcid.org/0000-0001-7878-7075</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0951-418X |
| ispartof | Phytotherapy research, 2019-07, Vol.33 (7), p.1921-1933 |
| issn | 0951-418X 1099-1573 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6618084 |
| source | MEDLINE; Wiley Online Library |
| subjects | Adiponectin Adult Anthropometry Antioxidants Biomarkers Blood glucose Blood Glucose - metabolism Blood pressure Citrus Diet Double-Blind Method Double-blind studies Female Flavanones - therapeutic use flavonoids Glucagon Glucose Glucose tolerance Glycated Hemoglobin A - metabolism Hemoglobin Hesperidin - therapeutic use Humans Hyperglycemia Hyperglycemia - drug therapy Hypoglycemic Agents - therapeutic use Inflammation Insulin Insulin Resistance Interleukins Intervention Intolerance Lipid peroxidation Lipids Male Metabolism Middle Aged Oxidative stress Peroxidation prediabetic state Prediabetic State - drug therapy Treatment Outcome Tumor necrosis factor-α |
| title | Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double‐blind, randomized, controlled study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T21%3A50%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20Eriomin%C2%AE%20in%20managing%20hyperglycemia%20and%20reversal%20of%20prediabetes%20condition:%20A%20double%E2%80%90blind,%20randomized,%20controlled%20study&rft.jtitle=Phytotherapy%20research&rft.au=Ribeiro,%20Carolina%20B.&rft.date=2019-07&rft.volume=33&rft.issue=7&rft.spage=1921&rft.epage=1933&rft.pages=1921-1933&rft.issn=0951-418X&rft.eissn=1099-1573&rft_id=info:doi/10.1002/ptr.6386&rft_dat=%3Cproquest_pubme%3E2265596499%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2265596499&rft_id=info:pmid/31183921&rfr_iscdi=true |